Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ventas

How Is Ventas' Stock Performance Compared to Other Real Estate Stocks?

Ventas has lagged behind its industry peers over the past year, yet Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Behind the Buy Signal: How Our Top Technical Trader Finds Bullish Stock Picks

Ventas stock just appeared on John Rowland’s favorite stock screener, but he’s looking for a confluence of indicators to find trade ideas.

Barchart

Ventas Trying To Close In On Key Technical Measure

Ventas shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Do Wall Street Analysts Like Ventas Stock?

Ventas has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.

Barchart

Ventas Earnings Preview: What to Expect

Ventas is slated to report its second-quarter results next week, with analysts expecting a measured, single-digit growth in earnings.

Barchart

Ventas Stock: Is VTR Outperforming the Real Estate Sector?

Ventas crushed its real estate peers over the past year but lost steam over the past few months. Still, analysts are upbeat about the stock's growth potential.

Barchart

Ventas Stock Outlook: Is Wall Street Bullish or Bearish?

Senior housing giant Ventas has significantly outpaced the broader market over the past year, and analysts remain bullish on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

What You Need to Know Ahead of Ventas' Earnings Release

Ventas will release its first-quarter earnings next week, and analysts anticipate a single-digit bottom-line growth.

Barchart

Analysts Say 12 Stocks Will Profit Most From Trump's Reign

First-quarter earnings season is in full swing. But investors playing the long game want to know which S&P 500 companies will profit most.

Investors Business Daily

Is Ventas Stock Outperforming the Dow?

Due to Ventas’s outperformance relative to the Dow Jones over the past year, analysts are bullish about the stock’s prospects.

Barchart

Ventas Shows Market Leadership With Jump To 91 RS Rating

A Relative Strength Rating upgrade for Ventas shows improving technical performance.

Investors Business Daily

Stocks With Rising Relative Price Strength: Ventas

Ventas sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

3 Healthcare REITs Offering Healthy Dividends

Healthcare REITs are delivering healthy dividends while capitalizing on the growing demand for medical facilities. In this article, we’ll explore three healthcare REITs, Welltower (WELL), Ventas (VTR), and National Health Investors (NHI) that could be added to your watchlist. Read on.

StockNews.com

Are Wall Street Analysts Predicting Ventas Stock Will Climb or Sink?

Ventas has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Ventas Stock Gets Relative Strength Rating Bump

A Relative Strength Rating upgrade for Ventas shows improving technical performance. Will it continue?

StockNews.com

3 Healthcare REITs Offering Healthy Dividend Yields

As the healthcare real estate market flourishes, fueled by demographic transformations and cutting-edge advancements in healthcare delivery, fundamentally robust stalwarts like Welltower (WELL), Ventas (VTR), and Omega Healthcare Investors (OHI) shine as premier investment opportunities. Dive deeper to discover how these REITs are shaping the future while delivering healthy returns.

Barchart

Is Ventas Stock Underperforming the Nasdaq?

Ventas has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.

Benzinga

Where Ventas Stands With Analysts

Throughout the last three months, 5 analysts have evaluated Ventas (NYSE:VTR), offering a diverse set of opinions from bullish to bearish.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Wall Street Bullish or Bearish on Ventas Stock?

Ventas has outperformed the broader market over the past year, and analysts remain moderately bullish on the stock’s prospects.

Barchart

What to Expect From Ventas' Q3 2024 Earnings Report

Ventas is gearing up to release its third-quarter earnings this month, and analysts expect a single-digit FFO increase.

StockNews.com

3 Healthcare REITs Offering Growth and Income Potential

The combination of demographic trends, increasing healthcare needs, and stable revenue structures makes the healthcare REITs industry poised for robust growth. Therefore, it could be wise to explore investments in robust REITs such as Ventas (VTR), Omega Healthcare Investors (OHI), and National Health Investors (NHI). Keep reading….

Barchart

Is Ventas Stock Outperforming the S&P 500?

Ventas outperformed the S&P 500 recently, and Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Ventas - A Place for Mom

Summary Ventas Inc. (VTR) is a leading senior living facility REIT with strong technical buy signals and a 35.09% gain since 5/2. The company boasts a $25.14 billion market cap, 2.90% dividend yield, and is expected to grow revenue by 7.30% this year. Analysts provide strong buy ratings with price...

Barchart

Are Wall Street Analysts Bullish on Ventas Stock?

Ventas has outperformed the broader market over the past year, and analysts remain moderately bullish on the stock’s prospects.

Barchart

Here's What to Expect From Ventas’ Next Earnings Report

Ventas is projected to unveil its second-quarter earnings next month, and analysts project a single-digit earnings growth.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Palantir Technologies

276 stories

Vertex Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.